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Plasma urotensin II levels in primary Raynaud’s phenomenon and systemic sclerosis
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Background/aim: The pathogenesis of Raynaud’s phenomenon (RP) has not yet been fully elucidated. RP is characterized by exaggerated
cold-induced vasoconstriction. Urotensin II (UII) is a potent vasoconstrictor. The aim of the present study was to evaluate plasma UII
levels in both primary RP and secondary RP associated with systemic sclerosis (SSc).
Materials and methods: Fifteen patients with primary RP, 30 patients with RP secondary to SSc, and 30 healthy controls (HC) were
included in the study. Raynaud condition scores (RCS) were determined in the primary RP and SSc groups. Modified Rodnan skin score
(MRSS) was determined for the SSc patients. Plasma UII level was analyzed by the ELISA method.
Results: When compared to the HC group, plasma UII level was lower in the secondary RP group, but not in the primary RP group.
Plasma UII level was not directly related to RCS in either the primary or secondary RP group. Moreover, it was not correlated with MRSS
in the secondary RP group.
Conclusion: The results of the present study suggest that UII is not associated with primary RP. Its level was lower in the secondary RP
(SSc) patients. Therefore, it can be concluded that decreased UII level is related to SSc instead of RP.
Key words: Urotensin II, Raynaud’s phenomenon, systemic sclerosis

1. Introduction
Raynaud’s phenomenon (RP) is an exaggerated vascular
response to cold weather and/or emotional stress. It
manifests with discoloration of distal parts of the body,
i.e. fingers and toes. RP occurring in patients without
any underlying disease is called primary (idiopathic) RP,
and cases related to systemic lupus erythematosus (SLE),
systemic sclerosis (SSc), mixed connective tissue disease,
Sjögren’s syndrome, or dermatomyositis/polymyositis are
called secondary RP. The most marked pathophysiologic
mechanism detected in RP is vasoconstriction. However,
its underlying mechanism is not fully known (1,2).
Increased levels of endothelin-1, which is a potent
vasoconstrictor, and decreased activity of nitric oxide
(NO), which is a potent vasodilator, have been detected in
patients with primary RP (3,4). These changes may explain
the mechanism of vasoconstriction in RP (3,4).
* Correspondence: kocassk@yahoo.com

Urotensin-2 (UII) is a peptide consisting of 11 amino
acids (5). UII was first isolated from the neurosecretory
system of a fish. However, nowadays it is known that UII
is also secreted from the human central nervous system,
spleen, kidneys, small bowel, adrenal glands, thymus,
vascular endothelium, heart, white blood cells, and liver.
UII receptors have been identified on vascular smooth
muscle cells (5). Therefore, UII has been suggested to
play a role in cardiovascular diseases and it has been
widely studied in cardiovascular diseases (5). Moreover,
the relationship between essential hypertension and UII
levels has been reported (6). Because UII is one of the
most potent vasoconstrictors in the body, its possible
role in the pathogenesis of RP has also been studied (7).
Buyukhatipoglu et al. (7) have shown that plasma UII level
is related to RP in patients with SLE.
Therefore, we aimed to investigate plasma UII levels in
primary RP and in RP secondary to SSc.
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2. Materials and methods
2.1. Participants
Fifteen patients with primary RP, 30 patients with RP
secondary to SSc, and 30 healthy control volunteers
(HC) were enrolled in the study. All participants were
female. Primary RP patients fulfilled the established
criteria (8), while the secondary RP group was established
from patients with SSc who fulfilled the criteria for the
American College of Rheumatology classification (9). The
HC group consisted of participants without any detected
inflammatory disease who came to the outpatient clinics
of the Department of Internal Medicine. Participants aged
<18 years and >65 years; those with malignant diseases,
cardiac disease, or communication problems; pregnant
women; and reluctant patients were excluded from the
study. The protocol of this study was approved by the
institutional ethics committee, and all of the participants
gave written informed consent before being enrolled in the
study.
2.2. Samples
Blood samples of 5 mL were obtained from the left
antecubital vein of each participant in the sitting position.
Blood samples were placed in tubes containing aprotinin.
The tubes were agitated slowly, placed on ice batteries, and
transferred to the biochemistry laboratory immediately.
The blood samples were centrifuged at 3500 rpm for 10
min at 4 °C. The obtained plasma samples were stored at
–20 °C until the day of analysis.
Plasma UII concentrations were measured using
an appropriate commercial kit (catalogue number:
yhb3169hu, Shanghai Yehua Biological Technology Co.,
Shanghai, China) with the ELISA method. The results
were expressed as ng/mL (CV [%] = SD / mean × 100;
intraassay: CV < 10%; interassay: CV < 12%; sensitivity:
2.23 ng/mL).
Raynaud’s condition score (RCS) is used to determine
frequency, duration, and severity of RP episodes (10).
RCSs of the patients in the primary and secondary RP
groups were recorded. In addition, modified Rodnan skin
scoring (MRSS) was used to determine the extent of skin
involvement in the secondary RP (SSc) group (11).
2.3. Statistical analysis
Data were analyzed using SPSS 21 (IBM Corp., Armonk,
NY, USA). Data were expressed as mean ± standard
deviation. The normal distribution of the variables was
evaluated with the Kolmogorov–Smirnov test. Parametric
data were analyzed with analysis of variance (ANOVA) and
the post hoc Tukey test, while nonparametric data were
analyzed with the Mann–Whitney U test. On the other
hand, analysis of covariance (ANCOVA) was also used to
adjust variables for age, blood pressure, and the levels of
fasting blood glucose. Categorical data were analyzed by
the chi-square test. Pearson correlation analysis was used
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to determine the relationship among the data. P < 0.05 was
considered significant.
3. Results
Demographic and clinical characteristics of the participants
are shown in the Table. The mean age was higher in the
secondary RP group compared to the HC group (P < 0.05).
The difference in terms of mean age between primary and
secondary RP groups was not statistically significant (P >
0.05).
Plasma UII level was significantly lower in the
secondary RP group (Figure) compared to the primary
RP and HC groups (P < 0.05 and P < 0.01, respectively).
Its level was lower in the primary RP group compared to
the HC group, although the difference was not statistically
significant (Table).
The mean RCSs were 6.33 ± 1.54 and 4.70 ± 2.38 in the
primary RP and secondary RP groups, respectively. There
was a significant difference between the 2 groups in terms
of mean RCS (P < 0.05). On the other hand, plasma UII
levels were not correlated with RCS in either group (P >
0.05). In the secondary RP group, mean MRSS was 13.07 ±
9.16. There was no significant correlation between MRSS
and plasma UII level (P > 0.05).
In the control group, plasma UII levels were negatively
correlated with diastolic blood pressure (r = –0.377, P
= 0.040). However, plasma UII level was not correlated
with systolic or diastolic blood pressure in either the
primary RP or the secondary RP group. None of the
participants had the diagnosis of hypertension in the HC
and primary RP groups, although 3 (10%) SSc patients
had hypertension (P = 0.096). Moreover, all SSc patient
were receiving an antihypertensive drug (24 patients were
taking nifedipine and 6 patients were taking losartan) due
to RP or hypertension.
Plasma UII levels were again evaluated statistically by
ANCOVA test because there were significant differences
among the groups in terms of mean age, blood pressure,
and fasting blood glucose levels. There was no significant
correlation between plasma UII and mean age in all the
groups. However, the decrease in plasma UII level in the
secondary RP group was not statistically significant after
adjusting for the mean age (ANCOVA, P > 0.05).
4. Discussion
The present study evaluated whether plasma UII level is
related to RP. For this purpose, plasma UII levels were
analyzed in patients with primary RP and secondary RP
(SSc). Plasma UII level was similar in healthy subjects and
primary RP patients. However, its level was decreased in
cases of RP secondary to SSc.
In both in vitro (12) and in vivo (13) studies, potent
vasoconstrictor effects of UII, like those of endothelin-1
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Table. The demographics and laboratory data in the study groups.
HC
(n = 15)

Primary RP
(n = 30)

Secondary RP
(n = 30)

P

Mean age (years)

27.6 ± 10

30.2 ± 7.9

49.4 ± 13a

0.001

Systolic BP (mmHg)

105 ± 20.3

111.1 ± 12.6

119 ± 17.6a

0.009

Diastolic BP (mmHg)

67 ± 7.2

76.0 ± 9.2

76 ± 10.2b

0.002

BMI (kg/m2)

25.3 ± 4.9

23.6 ± 4.8

26.4 ± 3.6

0.192

ESR (mm/h)

9.9 ± 8.2

7.1 ± 7.5

18.3 ± 11.1a,e

<0.001

CRP (mg/L)

3.9 ± 1.9

4.1 ± 1.8

4.5 ± 3.0c

0.007

Glucose (mg/dL)

86 ± 6.8

85.5 ± 8.6

105 ± 19.9b,d

0.001

TCL (mg/dL)

168.9 ± 32.5

158.9 ± 30.8

b,c

200.6 ± 44.1

0.002

LDL (mg/dL)

93.5 ± 20.1

93.5 ± 24.5

124.1 ± 41.0b,c

0.003

HDL (mg/dL)

54.3 ± 17.0

54.3 ± 16.5

52.4 ± 16.6

0.889

Triglyceride (mg/dL)

115.7 ± 9.9

101.4 ± 54.5

146.2 ± 108.7

0.203

Urotensin II (ng/mL)

669.1 ± 544.7

533.8 ± 380.2

291.9 ± 268.7b,c

0.001

Data are expressed as mean ± SD.
HC, Healthy controls; RP, Raynaud’s phenomenon; BP, blood pressure; BMI, body mass index; ESR, erythrocyte sedimentation rate;
CRP, C-reactive protein; TCL, total cholesterol; LDL, low-density cholesterol; HDL, high-density cholesterol.
When compared to the HC group: aP < 0.05, b P < 0.01.
When compared to the primary RP group: cP < 0.05, dP < 0.01, eP < 0.001.

Figure. Plasma urotensin II levels in the study groups.
SSc, Systemic sclerosis; RP, Raynaud’s phenomenon; HC, healthy controls.
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receptors, have been detected on both arteries and veins.
In many studies, the effects of UII on the pancreas (14),
pulmonary artery (15), and kidneys (16) have been
investigated. However, most studies have concentrated on
the cardiovascular system because of the vasoconstrictor
effects of UII. In addition to its vasoconstrictor effects,
these studies performed on the cardiovascular system
have demonstrated that UII can affect the pathogenesis
of atherosclerosis (17) and induce fibrosis, cardiac
hypertrophy, and coronary vasoconstriction (18). Contrary
to these unfavorable data (17,18), Babińska et al. (19)
documented the potential cardioprotective effects of UII.
In another study (20), it was shown that UII ameliorates
reperfusion injury in ischemic heart disease.
In RP, the most predominant and observable
pathophysiologic mechanism is vasoconstriction (1,2).
In RP, the level of endothelin-1, which is a potent
vasoconstrictor, increases (3), while the activity of NO,
which is a potent vasodilator, decreases (4). In a study on
patients with SLE (7), probable correlation between levels
of potent vasoconstrictor UII and RP was asserted. In the
aforementioned study (7), the investigators speculated
that UII is released from the vascular endothelium and
plays a role in the vasoconstriction phase of RP. In our
study, plasma UII levels were comparatively lower in the
secondary RP group, whereas in the primary RP group,
plasma UII levels were similar to those of the healthy
control group. In addition, plasma UII level was not
correlated with RCS in either the primary or the secondary
RP group. These results may suggest that plasma UII levels
are not related with RP, in contrast to the previous study
(7).
Raynaud’s phenomenon progresses with attacks. In
our study, none of the patients was experiencing an RP
attack during collection of plasma samples. It is difficult to
detect patients during RP attacks in order to enroll them
in a study. Therefore, the lack of any relation between
plasma UII level and RP in our study may be attributed
to this issue. It is accepted that UII has a relatively shorter
plasma half-life (21). In an in vivo study (21) using an
acute liver injury model, tissue UII levels peaked within 30
min, remained at that level for nearly 2 h, and normalized
within 6 h. Therefore, it may be claimed that UII levels
probably normalize soon after an episode of RP. Thus, it
may be speculated that the possible relation between UII
and RP could not be observed since patients were not
experiencing an RP attack in our study.
In contrast to primary RP, the relatively low plasma UII
level in RP secondary to SSc may indicate that plasma UII
level decreases due to SSc but not RP. It is widely known
that one of the earliest changes in the pathogenesis of SSc
is vascular dysfunction (22). The effects of UII on the
vascular system have been intensively investigated (17–
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20). Increased UII levels were reported in SSc patients (23).
Another important clinical finding of SSc is pulmonary
hypertension. Previous studies have demonstrated higher
UII levels in pulmonary hypertension (24,25). In our
study, decreased plasma UII levels were detected in the
SSc group.
Plasma UII level was unaltered in the primary RP
group, although it decreased in the secondary RP group.
Similarly, plasma UII level and RCS were not related in
either group. These results suggest that SSc and/or any
manifestations of SSc such as fibrosis may contribute
to the decrease in UII level, in contrast to RP. However,
plasma UII level in the secondary RP (SSc) group was not
significantly correlated with MRSS as in RCS. This result
may suggest that SSc, or at least skin fibrosis, cannot alter
the plasma UII level. It has been shown in an experimental
scleroderma model that UII level and skin fibrosis are not
correlated (26).
In the SSc group, mean age was relatively higher.
Additionally, it is known that the incidence of chronic
diseases such as hypertension and diabetes mellitus
increases with older age. Previous studies (13–16,18) have
shown that UII levels might increase in diseases related to
endothelial dysfunction, including essential hypertension,
diabetes mellitus, atherosclerosis, ischemic heart disease,
and heart failure.
In our study, in the secondary RP group, systolic blood
pressure was significantly higher when compared with
the control group. Plasma glucose levels in the secondary
RP group were significantly higher when compared with
both the control and primary RP groups. In our study,
we also analyzed the correlation between plasma UII
and lipid levels. In all the groups, lipid parameters were
within normal limits. However, we determined relatively
higher total cholesterol and LDL cholesterol levels in the
secondary RP group compared to the healthy control
and primary RP groups. In all the groups, there was no
significant correlation among the blood lipids and plasma
UII levels. However, despite increased levels of relevant
pathologies in the secondary RP group, UII levels were not
increased, but decreased.
It is widely known that hypertension affects UII level;
this subject has been investigated in many studies (6,19).
In some studies, increased UII levels have been reported
(6). However, some other studies have demonstrated a
lack of any significant difference between patients with
and without hypertension (19). Mosenkis et al. (27)
refuted the presence of a correlation between UII level
and blood pressure. Despite all of these reports, the effects
of antihypertensive treatments on UII levels have not
been investigated so far. In our study, the patients in the
secondary RP group were using a vasodilator in order
to be able to decrease the frequency of RP episodes. Use
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of nifedipine or angiotensin receptor antagonists could
probably suppress plasma UII levels.
On the other hand, renal dysfunction is frequently seen
in patients with SSc (28). UII can be produced in many
parts of the body (5). The kidney is one of the production
sites of UII (5). Mosenkis et al. (27) revealed that plasma
UII levels decrease in renal failure, and plasma UII level
is inversely correlated with creatinine level. Decreased
renal function in SSc patients may be another reason for
decreased plasma UII levels. This may explain the lack of
any correlation between plasma UII level and MRSS.

Our study has some limitations. For example, power
analysis was not performed to ascertain the counts of
participants in the groups. Second, the patients were not
evaluated during RP attacks. Despite these limitations,
our study can provide an example for further studies to be
performed on this topic.
In conclusion, plasma UII level decreased in RP related
to SSc, although it was not altered in primary RP. It may
be concluded that UII levels are not related to RP. Its level
decreases in secondary RP patients associated with SSc,
but not due to RP.
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